{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T13:52:58Z","timestamp":1772891578970,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T00:00:00Z","timestamp":1682294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T00:00:00Z","timestamp":1682294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>As messenger RNA (mRNA)-based vaccines for coronavirus disease 2019 (COVID-19) have been administered to millions of individuals worldwide, cases of de novo and relapsing glomerulonephritis after mRNA COVID-19 vaccination are increasing in the literature. While most previous publications reported glomerulonephritis after the first or second dose of an mRNA vaccine, few reports of glomerulonephritis occurring after the third dose of an mRNA vaccine currently exist.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>We report a case of rapidly progressive glomerulonephritis in a patient following the third dose of an mRNA COVID-19 vaccine. A 77-year-old Japanese man with a history of hypertension and atrial fibrillation was referred to our hospital for evaluation of anorexia, pruritus, and lower extremity edema. One year before referral, he received two mRNA vaccines (BNT162b2) for COVID-19. Three months before the visit, he received a third mRNA vaccine (mRNA-1273) for COVID-19. On admission, the patient presented severe renal failure with a serum creatinine level of 16.29\u00a0mg\/dL, which had increased from 1.67\u00a0mg\/dL one month earlier, prompting us to initiate hemodialysis. Urinalysis showed nephrotic-range proteinuria and hematuria. Renal biopsy revealed mild mesangial proliferation and expansion, a lobular appearance, and double contours of the glomerular basement membrane. Renal tubules had severe atrophy. Immunofluorescence microscopy showed strong mesangial staining for IgA, IgM, and C3c. Electron microscopy exhibited mesangial and subendothelial electron-dense deposits, leading to a diagnosis of IgA nephropathy with membranoproliferative glomerulonephritis-like changes. The kidney function remained unchanged after steroid therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Although the link between renal lesions and mRNA vaccines remains unclear, a robust immune response induced by mRNA vaccines may play a role in the pathogenesis of glomerulonephritis. Further studies of the immunological effects of mRNA vaccines on the kidney are warranted.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12882-023-03169-3","type":"journal-article","created":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T09:04:10Z","timestamp":1682327050000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Rapidly progressive IgA nephropathy with membranoproliferative glomerulonephritis-like lesions in an elderly man following the third dose of an mRNA COVID-19 vaccine: a case report"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8330-002X","authenticated-orcid":false,"given":"Nobuhisa","family":"Morimoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayasu","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Shioji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Towako","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hatsumi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keigo","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuo","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayumi","family":"Yamamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asami","family":"Hanioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Akagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamami","family":"Fujiki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shintaro","family":"Mandai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaro","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumiaki","family":"Ando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichiro","family":"Susa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soichiro","family":"Iimori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shotaro","family":"Naito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eisei","family":"Sohara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,24]]},"reference":[{"issue":"1","key":"3169_CR1","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s12916-022-02397-y","volume":"20","author":"B Zeng","year":"2022","unstructured":"Zeng B, Gao L, Zhou Q, Yu K, Sun F. Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis. BMC Med. 2022;20(1):200.","journal-title":"BMC Med"},{"issue":"10309","key":"3169_CR2","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/S0140-6736(21)02183-8","volume":"398","author":"SY Tartof","year":"2021","unstructured":"Tartof SY, Slezak JM, Fischer H, Hong V, Ackerson BK, Ranasinghe ON, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021;398(10309):1407\u201316.","journal-title":"Lancet"},{"key":"3169_CR3","doi-asserted-by":"publisher","unstructured":"Monge S, Rojas-Benedicto A, Olmedo C, Mazagatos C, Jos\u00e9 Sierra M, Limia A, et al. Effectiveness of mRNA vaccine boosters against infection with the SARS-CoV-2 omicron (B.1.1.529) variant in Spain: a nationwide cohort study. Lancet Infect Dis. 2022; Available from: http:\/\/dx.doi.org\/https:\/\/doi.org\/10.1016\/S1473-3099(22)00292-4","DOI":"10.1016\/S1473-3099(22)00292-4"},{"key":"3169_CR4","unstructured":"COVID-19 Vaccine Booster Shots (3rd Dose). Japanese Ministry of Health, Labour and Welfare. Accessed on July 23, 2022. Available at: https:\/\/www.mhlw.go.jp\/stf\/covid-19\/booster.html"},{"issue":"4","key":"3169_CR5","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1159\/000523962","volume":"53","author":"R Fenoglio","year":"2022","unstructured":"Fenoglio R, Lalloni S, Marchisio M, Oddone V, De Simone E, Del Vecchio G, et al. New onset biopsy-proven nephropathies after COVID vaccination. Am J Nephrol. 2022;53(4):325\u201330.","journal-title":"Am J Nephrol"},{"issue":"12","key":"3169_CR6","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1016\/j.ekir.2021.09.008","volume":"6","author":"N Klomjit","year":"2021","unstructured":"Klomjit N, Alexander MP, Fervenza FC, Zoghby Z, Garg A, Hogan MC, et al. COVID-19 Vaccination and glomerulonephritis. Kidney Int Rep. 2021;6(12):2969\u201378.","journal-title":"Kidney Int Rep"},{"issue":"1","key":"3169_CR7","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/nep.13992","volume":"27","author":"WK Lo","year":"2022","unstructured":"Lo WK, Chan KW. Gross haematuria after mRNA COVID-19 vaccination in two patients with histological and clinical diagnosis of IgA nephropathy. Nephrology. 2022;27(1):110\u20131.","journal-title":"Nephrology"},{"issue":"4","key":"3169_CR8","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1053\/j.ajkd.2021.06.004","volume":"78","author":"AS Bomback","year":"2021","unstructured":"Bomback AS, Kudose S, D\u2019Agati VD. De novo and relapsing glomerular diseases after COVID-19 vaccination: what do we know so far? Am J Kidney Dis. 2021;78(4):477\u201380.","journal-title":"Am J Kidney Dis"},{"key":"3169_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.617089","volume":"11","author":"A Vojdani","year":"2020","unstructured":"Vojdani A, Vojdani E, Kharrazian D. Reaction of human monoclonal antibodies to SARS-CoV-2 proteins with tissue antigens: implications for autoimmune diseases. Front Immunol. 2020;11: 617089.","journal-title":"Front Immunol"},{"issue":"1","key":"3169_CR10","doi-asserted-by":"publisher","first-page":"c18","DOI":"10.1159\/000324180","volume":"119","author":"SH Nasr","year":"2011","unstructured":"Nasr SH, D\u2019Agati VD. IgA-dominant postinfectious glomerulonephritis: a new twist on an old disease. Nephron Clin Pract. 2011;119(1):c18-25 discussion c26.","journal-title":"Nephron Clin Pract."},{"key":"3169_CR11","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1\u2013S276."},{"issue":"22","key":"3169_CR12","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.2169\/internalmedicine.52.0420","volume":"52","author":"A Shimizu","year":"2013","unstructured":"Shimizu A, Takei T, Moriyama T, Itabashi M, Uchida K, Nitta K. Clinical and pathological studies of IgA nephropathy presenting as a rapidly progressive form of glomerulonephritis. Intern Med. 2013;52(22):2489\u201394.","journal-title":"Intern Med"},{"issue":"12","key":"3169_CR13","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1681\/ASN.2012101017","volume":"24","author":"J Lv","year":"2013","unstructured":"Lv J, Yang Y, Zhang H, Chen W, Pan X, Guo Z, et al. Prediction of outcomes in crescentic IgA nephropathy in a multicenter cohort study. J Am Soc Nephrol. 2013;24(12):2118\u201325.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"3169_CR14","doi-asserted-by":"publisher","first-page":"168","DOI":"10.4103\/0971-4065.145425","volume":"25","author":"V Agrawal","year":"2015","unstructured":"Agrawal V, Kaul A, Ranade RS, Sharma RK. Immunoglobulin A dominant membranoproliferative glomerulonephritis in an elderly man: A case report and review of the literature. Indian J Nephrol. 2015;25(3):168\u201370.","journal-title":"Indian J Nephrol"},{"issue":"4","key":"3169_CR15","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s10157-003-0253-z","volume":"7","author":"K Iitaka","year":"2003","unstructured":"Iitaka K, Yamamoto A, Ogawa N, Sekine T, Tamai S, Motoyama O. IgA-associated glomerulonephritis with membranoproliferative glomerulonephritis-like pattern in two children. Clin Exp Nephrol. 2003;7(4):284\u20139.","journal-title":"Clin Exp Nephrol"},{"issue":"6","key":"3169_CR16","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S0272-6386(97)90456-X","volume":"29","author":"M Haas","year":"1997","unstructured":"Haas M. Histologic subclassification of IgA nephropathy: a clinicopathologic study of 244 cases. Am J Kidney Dis. 1997;29(6):829\u201342.","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"3169_CR17","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1093\/ckj\/sfu090","volume":"7","author":"E Wallace","year":"2014","unstructured":"Wallace E, Maillard N, Ueda H, Hall S, Fatima H, Novak J, et al. Immune profile of IgA-dominant diffuse proliferative glomerulonephritis. Clin Kidney J. 2014;7(5):479\u201383.","journal-title":"Clin Kidney J"},{"issue":"13","key":"3169_CR18","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1097\/QAD.0b013e32835612f0","volume":"26","author":"YJ Kim","year":"2012","unstructured":"Kim YJ, Kim SI, Choi YJ, Kang MW. Immunoglobulin A-dominant postinfectious glomerulonephritis in a patient with acute HIV syndrome. AIDS. 2012;26(13):1725\u20136.","journal-title":"AIDS"},{"issue":"2","key":"3169_CR19","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00467-021-05351-x","volume":"37","author":"O Niel","year":"2022","unstructured":"Niel O, Florescu C. IgA nephropathy presenting as rapidly progressive glomerulonephritis following first dose of COVID-19 vaccine. Pediatr Nephrol. 2022;37(2):461\u20132.","journal-title":"Pediatr Nephrol"},{"issue":"12","key":"3169_CR20","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1681\/ASN.2022030258","volume":"33","author":"M Canney","year":"2022","unstructured":"Canney M, Atiquzzaman M, Cunningham AM, Zheng Y, Er L, Hawken S, et al. A population-based analysis of the risk of glomerular disease relapse after COVID-19 vaccination. J Am Soc Nephrol. 2022;33(12):2247\u201357.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"3169_CR21","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.kint.2019.08.022","volume":"97","author":"Y Makita","year":"2020","unstructured":"Makita Y, Suzuki H, Kano T, Takahata A, Julian BA, Novak J, et al. TLR9 activation induces aberrant IgA glycosylation via APRIL- and IL-6-mediated pathways in IgA nephropathy. Kidney Int. 2020;97(2):340\u20139.","journal-title":"Kidney Int"},{"issue":"7","key":"3169_CR22","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.2169\/internalmedicine.8787-21","volume":"61","author":"Y Nihei","year":"2022","unstructured":"Nihei Y, Kishi M, Suzuki H, Koizumi A, Yoshida M, Hamaguchi S, et al. IgA nephropathy with gross hematuria following COVID-19 mRNA vaccination. Intern Med. 2022;61(7):1033\u20137.","journal-title":"Intern Med"},{"issue":"4","key":"3169_CR23","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41577-021-00526-x","volume":"21","author":"JR Teijaro","year":"2021","unstructured":"Teijaro JR, Farber DL. COVID-19 vaccines: modes of immune activation and future challenges. Nat Rev Immunol. 2021;21(4):195\u20137.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"3169_CR24","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41541-021-00391-8","volume":"6","author":"R Sartorius","year":"2021","unstructured":"Sartorius R, Trovato M, Manco R, D\u2019Apice L, De Berardinis P. Exploiting viral sensing mediated by Toll-like receptors to design innovative vaccines. NPJ Vaccines. 2021;6(1):127.","journal-title":"NPJ Vaccines"},{"key":"3169_CR25","doi-asserted-by":"publisher","unstructured":"Zheng N, Xie K, Ye H, Dong Y, Wang B, Luo N, et al. TLR7 in B cells promotes renal inflammation and Gd-IgA1 synthesis in IgA nephropathy. JCI Insight. 2020;5(14). Available from: https:\/\/doi.org\/10.1172\/jci.insight.136965","DOI":"10.1172\/jci.insight.136965"},{"issue":"1","key":"3169_CR26","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/ki.1995.25","volume":"47","author":"A Koyama","year":"1995","unstructured":"Koyama A, Kobayashi M, Yamaguchi N, Yamagata K, Takano K, Nakajima M, et al. Glomerulonephritis associated with MRSA infection: a possible role of bacterial superantigen. Kidney Int. 1995;47(1):207\u201316.","journal-title":"Kidney Int"},{"issue":"1","key":"3169_CR27","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ekir.2021.10.007","volume":"7","author":"S Itami","year":"2022","unstructured":"Itami S, Moriyama T, Miyabe Y, Karasawa K, Nitta K. A novel scoring system based on Oxford classification indicating steroid therapy use for IgA nephropathy. Kidney Int Rep. 2022;7(1):99\u2013107.","journal-title":"Kidney Int Rep"},{"key":"3169_CR28","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.humpath.2018.06.031","volume":"81","author":"NK Andeen","year":"2018","unstructured":"Andeen NK, Jefferson JA, Akilesh S, Alpers CE, Bissonnette ML, Finn LS, et al. IgA-dominant glomerulonephritis with a membranoproliferative pattern of injury. Hum Pathol. 2018;81:272\u201380.","journal-title":"Hum Pathol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-023-03169-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-023-03169-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-023-03169-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T09:08:30Z","timestamp":1682327310000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-023-03169-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,24]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3169"],"URL":"https:\/\/doi.org\/10.1186\/s12882-023-03169-3","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,24]]},"assertion":[{"value":"5 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal. The research was conducted ethically in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"108"}}